5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.

5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.

BACKGROUND and AIMS: This study was performed to quantify the risk of renal disease in patients using aminosalicylates (5-ASA). METHODS: Data from the United Kingdom General Practice Research Database were used to estimate the incidence of renal disease in adult patients with inflammatory bowel dis...

Bibliografske podrobnosti
Main Authors:	Van Staa, T, Travis, S, Leufkens, H, Logan, R
Format:	Journal article
Jezik:	English
Izdano:	2004

Podobne knjige/članki

Renal Effects of Long-Term Treatment with 5-Aminosalicylic Acid
od: Harshna Patel, et al.
Izdano: (2009-01-01)

Sonoelectrochemically enhanced determination of 5-aminosalicylic acid.
od: Beckett, E, et al.
Izdano: (2001)

Therapy of Inflammatory Bowel Disease using 5-Aminosalicylic Acid, 4-Aminosalicylic Acid and Olsalazine Retention Enemas: Review of Clinical Trials
od: M. Campieri, et al.
Izdano: (1989-01-01)

Mechanism of action of 5-aminosalicylic acid and its derivatives.
od: Ireland, A, et al.
Izdano: (1990)

Electroanalytical Overview: The Sensing of Mesalamine (5-Aminosalicylic Acid)
od: Robert D. Crapnell, et al.
Izdano: (2023-12-01)

Lupus-Like Syndrome Caused by 5-Aminosalicylic Acid in Patients with Inflammatory Bowel Disease
od: Andrew W Kirkpatrick, et al.
Izdano: (1999-01-01)

Pharmacokinetics of 5-Aminosalicylic Acid Enteral Suspension in Crohn's Disease Patients and Normal Volunteers
od: CN Williams, et al.
Izdano: (1990-01-01)

Aminosalicylates in inflammatory bowel disease
od: Vojislav N. Perisic
Izdano: (2013-10-01)

Controlled Release of 5-Aminosalicylic Acid (5-ASA) from New Biodegradable Polyurethanes
od: El-Refaie Kenawy, et al.
Izdano: (2010-03-01)

Does a fracture at one site predict later fractures at other sites? A British cohort study.
od: van Staa, T, et al.
Izdano: (2002)

Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells.
od: Ireland, A, et al.
Izdano: (1990)

Efficacy of 5-Aminosalicylic Acid Enemas in the Treatment of Distal Ulcerative Colitis
od: MG Robinson, et al.
Izdano: (1990-01-01)

Flavonoids and 5-Aminosalicylic Acid Inhibit the Formation of Neutrophil Extracellular Traps
od: Tina Kirchner, et al.
Izdano: (2013-01-01)

Perimyocarditis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
od: Hye Young Lee, et al.
Izdano: (2024-05-01)

The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
od: Long He, et al.
Izdano: (2021-05-01)

5-Aminosalicylic Acid Chemoprevention in Inflammatory Bowel Diseases: Is It Necessary in the Age of Biologics and Small Molecules?
od: Hans Herfarth, et al.
Izdano: (2021-09-01)

Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid
od: Ashok K. Batta, et al.
Izdano: (1998-08-01)

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis.
od: van Staa, T, et al.
Izdano: (2002)

Studies on the acetylating capacity of human colonic epithelial cells for 5-aminosalicylic acid.
od: Ireland, A, et al.
Izdano: (1988)

5-Aminosalicylic Acid Enemas in the Maintenance of Remission in Distal Ulcerative Colitis and Proctitis
od: Lloyd R Sutherland, et al.
Izdano: (1987-01-01)

Unveiling the Unexplored Multifactorial Potential of 5-Aminosalicylic Acid in Diabetic Wound Therapy
od: Bharat Kumar Reddy Sanapalli, et al.
Izdano: (2024-08-01)

5-aminosalicylic acid suppresses osteoarthritis through the OSCAR-PPARγ axis
od: Jihee Kim, et al.
Izdano: (2024-02-01)

Effect of intra-abdominally administered mesalazine (5-aminosalicylic acid) in experimental peritonitis
od: Aziz Şener, et al.
Izdano: (2018-09-01)

USE OF 5-AMINOSALICYLIC ACID FOR TREATMENT OF ULCERATIVE COLITIS IN DIFFERENT DOSAGE MODES
od: M. V. Shapina, et al.
Izdano: (2017-11-01)

5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis
od: Hyo Yeop Song, et al.
Izdano: (2022-01-01)

Synthesis and evaluation of a prodrug of 5-aminosalicylic acid for the treatment of ulcerative colitis
od: Yan Yan, et al.
Izdano: (2019-12-01)

5-Aminosalicylic Acid Alters the Gut Bacterial Microbiota in Patients With Ulcerative Colitis
od: Jun Xu, et al.
Izdano: (2018-06-01)

Epidemiology of fractures in England and Wales.
od: van Staa, T, et al.
Izdano: (2001)

The epidemiology of fractures in England and Wales
od: van Staa, T, et al.
Izdano: (2001)

Colitis and Crohn’s Foundation (India) consensus statements on use of 5-aminosalicylic acid in inflammatory bowel disease
od: Ajit Sood, et al.
Izdano: (2020-10-01)

Five-Aminosalicylic Acid: An Update for the Reappraisal of an Old Drug
od: Cristiana Perrotta, et al.
Izdano: (2015-01-01)

Effect of High Dose Aminosalicylic Acid on Gastroduodenal Mucosa
od: DJ Leddin, et al.
Izdano: (1993-01-01)

5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis
od: Shinta Mizuno, et al.
Izdano: (2020-01-01)

5-Aminosalicylic acid inhibits the impaired epithelial barrier function induced by gamma interferon.
od: Paolo, D, et al.
Izdano: (1996)

Characteristics of Mucosa-Associated Microbiota in Ulcerative Colitis Patients with 5-Aminosalicylic Acid Intolerance
od: Hiroshi Matsumoto, et al.
Izdano: (2024-09-01)

Prevention of Relapse in Ulcerative Colitis Using Oral or Topical 5-Aminosalicylic Acid Therapy
od: Lloyd R Sutherland
Izdano: (1993-01-01)

Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis
od: Soo-Kyung Park, et al.
Izdano: (2022-09-01)

Preparation and in-vitro characterization of 5-aminosalicylic acid loaded hydrogels for colon specific delivery
od: Muhammad Suhail, et al.
Izdano: (2022-11-01)

Synthesis, characterization and radical scavenging activity of aromatic amine conjugates of 5-aminosalicylic acid
od: K. Harveer,, et al.
Izdano: (2014-09-01)

Preparation and evaluation of magnetic microspheres of mesalamine (5-aminosalicylic acid) for colon drug delivery
od: Satinder Kakar, et al.
Izdano: (2013-01-01)